Trial Profile
Use of Rifaximin in Patients With Functional Dyspepsia: A Randomized Controlled Trial
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 02 Feb 2017
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; Non-ulcer dyspepsia
- Focus Therapeutic Use
- 23 Jan 2017 Primary endpoint has been met. (Adequate relief of global dyspeptic symptoms at week 8.), as per an article published in the Alimentary Pharmacology and Therapeutics.
- 23 Jan 2017 Primary endpoint has not been met. (Adequate relief of global dyspeptic symptoms at week 4), as per an article published in the Alimentary Pharmacology and Therapeutics.
- 23 Jan 2017 Primary endpoint has not been met. (Global symptom improvement), as per an article published in the Alimentary Pharmacology and Therapeutics.